United Kingdom Precision Oncology Market Research Report: Forecast (2026-2032)

United Kingdom Precision Oncology Market Size: Forecast (2026- 2032)

The United Kingdom Precision Oncology Market size is valued at around USD 2.8 billion in 2025 and is projected to reach USD 4.3 billion by 2032. Along with this, the market is estimated to grow at a CAGR of around 7.19% during the forecast period, i.e., 2026-32. The United Kingdom Precision Oncology Market is accelerating rapidly as cancer prevalence rises, diagnostic activity expands, and advanced genomic technologies become central to treatment decision-making.

For instance, in April 2025, 264,880 people were assessed following an Urgent Suspected Cancer referral, averaging over 13,000 patients per working day, a 6.8% rise compared with April 2024. During the same period, 55,011 individuals commenced cancer treatment, meaning more than 2,500 patients started therapy each working day, reflecting a 4.7% month-on-month increase.

Between November 2023 and October 2024, more than 3 million people in England underwent urgent cancer checks, reflecting an increase of roughly 100,000 from the previous year and 700,000 more than pre-COVID levels.

The UK government allocated USD 2.9 billion to strengthen national imaging and diagnostic infrastructure, a move that has significantly accelerated the rollout of Community Diagnostic Centres (CDCs) across England. These centers are designed to expand testing capacity, reduce waiting times, and support earlier, more precise detection of cancer and other critical conditions.

Simultaneously, the expansion of genomic infrastructure through Genomics England and the NHS Genomic Medicine Service is embedding whole-genome sequencing, comprehensive biomarker panels, and AI-assisted genomic interpretation into routine oncology practice.

Government support continues to be a major catalyst for precision oncology expansion. For 2025/26, the UK allocated USD 2.11 billion for secondary and emergency care, including USD 768 million specifically for diagnostics. The funding will enhance existing Community Diagnostic Centres and add up to five new centers, many operating extended hours under the Elective Reform Plan. Alongside rising cancer detections and growing adoption of non-invasive genomic technologies, these investments position precision oncology for strong growth through the late 2020s.

United Kingdom Precision Oncology Market Recent Developments:

• May 2025: BioNTech committed up to USD1.33 billion to expand UK personalized oncology research, supported by a USD172.05 million government grant. The plan includes two new R&D centers, over 400 jobs, and strengthened national capabilities in advanced cancer therapeutics.

• May 2025: NHS England began making a “revolutionary” blood test (liquid biopsy) available across England for eligible lung- and breast-cancer patients. The test detects tiny fragments of circulating tumor DNA (ctDNA), enabling genomic results within days rather than weeks, helping patients access targeted therapies earlier and avoid some invasive biopsies or unnecessary chemotherapy. The NHS estimates up to 15,000 patients with suspected lung cancer and around 5,000 with advanced breast cancer could benefit annually.

United Kingdom Precision Oncology Market Scope:

United Kingdom Precision Oncology Market Drivers:

Rising Cases of Cancer & Earlier Diagnosis

The sustained rise in cancer diagnoses, combined with significant improvements in early detection across England, continues to expand the demand for precision-oncology solutions. For instance, the NDRS Cancer Registration Statistics 2023 reported 354,820 newly diagnosed cases, marking the highest volume recorded to date and reflecting the upward trend extending into 2024–2025.

Meanwhile, NHS England’s most recent 2025 update further indicates a notable shift toward earlier identification between September 2023 and August 2024, 58.7% of cancers across the 13 most common tumor types were detected at stage 1 or 2, the highest rate ever achieved. This represents 206,038 diagnoses, including approximately 120,958 early-stage cases, which is 7,000 more than expected under pre-pandemic patterns.

Diagnostic activity has also intensified. For instance, in February 2025, the NHS recorded an average of 12,615 urgent suspected-cancer referrals per working day, reflecting a 33% increase over pre-COVID levels. Moreover, 76.7% of patients received a definitive cancer/no-cancer outcome within the 28-day Faster Diagnosis Standard, shortening the pathway to molecular testing and targeted treatment eligibility.

Post-2025, national plans to expand Community Diagnostic Centers, mobile screening programmes, and genomic testing capacity will further raise detection volumes and accelerate adoption of precision-oncology technologies.

Overall, rising incidence, earlier detection, and faster diagnostic confirmation collectively increase the number of patients eligible for genomics-guided therapies, solidifying this driver as a major catalyst for precision-oncology market expansion through the late 2020s.

United Kingdom Precision Oncology Market Trends:

Increasing Adoption of Liquid Biopsy and Non-Invasive Tests

The growing shift toward minimally invasive diagnostic pathways has become a defining trend in the United Kingdom Precision Oncology Market, significantly reshaping how cancers are detected, monitored, and treated.

The NHS Genomic Medicine Service documented over 810,000 genomic tests conducted in 2024, marking an 8% rise from 2023, which reflects the system’s expanding sequencing capacity and deeper clinical integration of molecular diagnostics. The scale-up of ctDNA testing aligns closely with this growth, enabling faster delivery of actionable genomic insights and reducing the need for tissue-based sampling.

Early implementation studies have also highlighted notable efficiencies. Pilot programmes evaluating ctDNA in lung-cancer pathways identified potential savings of USD14 million per year by lowering reliance on invasive diagnostics and shortening the time to targeted-therapy initiation.

Looking beyond 2025, national commitments to strengthen genomics and artificial intelligence will further support liquid-biopsy expansion. For instance, the UK’s USD102 million AI investment announced in February 2025, coupled with ongoing funding for Community Diagnostic Centers and enhancements to national genomic infrastructure, is expected to drive broader uptake of non-invasive cancer testing.

As genomic testing volumes rise and government-backed innovation accelerates, liquid biopsy will become increasingly central to cancer care. These initiatives will broaden precision-oncology adoption, expand clinical testing volumes, and reinforce market growth through the late 2020s.

United Kingdom Precision Oncology Market Challenges:

High Cost of Precision-Medicine Treatments

Precision Oncology’s high treatment costs remain one of the most significant structural challenges for the United Kingdom. For instance, NHS England allocated USD 435 million to the Cancer Drugs Fund in 2023/24, underscoring the scale of resources required to manage high-cost, innovative cancer medicines.

High-value precision treatments exert further pressure on specialized-care budgets, which totaled USD 32 billion in 2023/24, reflecting ongoing reliance on public financing for advanced oncology interventions.

Treatment-level costs reinforce this challenge as CAR-T cell therapies such as tisagenlecleucel carry list prices around USD 361,000 per patient, creating substantial per-case expenditure for the NHS. Targeted therapeutics add similarly heavy cost obligations; for example, annual therapy costs for trastuzumab deruxtecan exceed USD 165,000 in published health-economic estimates.

Together, these escalating therapy prices and system-wide budget pressures show that high treatment costs remain a central barrier to expanding precision oncology access in the UK, challenging long-term financial sustainability and limiting the scale at which advanced innovations can be deployed.

United Kingdom Precision Oncology Market (2026-32) Segmentation Analysis:

The United Kingdom Precision Oncology Market Report and Forecast 2026-2032 offers a detailed analysis of the market based on the following segments:

Based on Product Type

• Diagnostics
  • Genomics
  • Transcriptomics
  • Proteomics
  • Epigenomics
  • Pharmacogenomics
  • Digital Pathology
  • Bioinformatics
• Therapeutics
  • Targeted Therapy
  • Immunotherapy
  • Hormone Therapy
  • Chemotherapy
  • Radiotherapy
  • Others

The diagnostics segment, especially genomics, holds the top spot in the United Kingdom Precision Oncology Market, as it forms the foundational step that enables all subsequent precision-therapy decisions.

Diagnostic technologies such as genomic sequencing, biomarker profiling, digital pathology, and bioinformatics are now embedded across clinical pathways, making them essential for identifying tumor mutations, selecting personalized therapies, and monitoring treatment response. These tools provide clinicians with high-resolution molecular insights, allowing earlier detection, better classification of cancers, and more accurate prediction of therapeutic effectiveness.

Additionally, government-backed initiatives such as the 100,000 Genomes Project and ongoing Genomics England programmes continue to prioritize genomic screening, variant detection, and bioinformatics infrastructure.

In contrast, the therapeutics segment, while clinically transformative, faces higher adoption barriers due to elevated treatment costs, reimbursement evaluations, and the need for specialized infrastructure. Therapeutic precision medicines also depend on diagnostic confirmation before they can be administered, which naturally positions diagnostics as the primary driver of precision-oncology workflows.

Overall, Diagnostics leads because it is universally required, scalable across all tumor types, and central to enabling targeted therapies, immunotherapies, and personalized treatment plans.

Based on End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Pharmaceutical & Biotechnology Companies
• Research & Academic Institutes
• Others

The hospitals and clinics category leads the United Kingdom Precision Oncology Industry, as they serve as the primary point of diagnosis, treatment, and clinical decision-making for cancer patients.

Most precision-oncology workflows, including biopsy collection, genomic testing requests, treatment selection, and patient monitoring, originate and are coordinated within hospital settings. These institutions host multidisciplinary cancer teams, integrate molecular tumor boards, and have direct access to advanced diagnostic tools and electronic health systems, allowing seamless incorporation of precision-medicine insights into routine care.

Hospitals also manage complex therapeutic interventions such as targeted therapies, immunotherapies, radiotherapy, and chemotherapy, all of which require specialized facilities, regulatory oversight, and experienced clinicians.

While diagnostic laboratories play a key role in processing genomic and molecular tests, their services typically feed back into hospital-led treatment pathways. Academic and research institutes contribute to innovation, but are not the primary users at scale. Overall, hospitals and clinics lead due to their central role in patient management, comprehensive infrastructure, and responsibility for implementing personalized treatment plans.

Leading Players of the United Kingdom Precision Oncology Market:

• Thermo Fisher Scientific Inc.

Thermo Fisher was founded in 1956, is headquartered in Waltham, Massachusetts, USA. The company specializes in providing scientific consumables, analytical instruments, laboratory reagents, and services for research, diagnostics, pharmaceutical, and biotechnology industries. Their product portfolio spans laboratory equipment, diagnostic tools, and life sciences services.

• AstraZeneca plc

Established in 1999 through the merger of Astra AB and Zeneca Group, AstraZeneca is headquartered in Cambridge, England. The company is a major global biopharmaceutical firm with expertise in discovering, developing, and commercializing medicines across therapeutic areas, including oncology, cardiovascular, respiratory, gastrointestinal, and more.

• Qiagen N.V.

Qiagen was founded in 1984. It specializes in molecular diagnostics and sample-to-insight technologies, providing kits and platforms for DNA/RNA/protein extraction, assay systems, PCR, next-generation sequencing prep, and bioinformatics, serving diagnostics, academic research, pharmaceutical, and biotech sectors.

Illumina, Inc., GlaxoSmithKline plc (GSK), Exact Sciences Corporation, NeoGenomics Laboratories, Inc., GRAIL, Inc., Guardant Health, Inc., and others are the key players of the United Kingdom Precision Oncology Market.

United Kingdom Precision Oncology Market (2026-32): Regional Projection

The United Kingdom Precision Oncology Market is dominated by the England region, primarily due to its advanced clinical infrastructure, large-scale genomic programmes, and stronger investment flows compared with other regions.

The presence of major national initiatives such as Genomics England, the NHS Genomic Medicine Service, and multiple NHS Genomic Laboratory Hubs gives England a more extensive ecosystem for integrating genomics, bioinformatics, and precision-based therapeutic pathways into routine care.

England also hosts the highest concentration of specialist cancer centers, research hospitals, pharmaceutical R&D hubs, and clinical trial networks, which accelerate rapid adoption of targeted therapies, companion diagnostics, and next-generation sequencing platforms.

In contrast, Scotland, Wales, and Northern Ireland are progressing but operate on comparatively smaller budgets and research capacities. As a result, England maintains the largest patient throughput, most comprehensive genomic data resources, and the strongest industry-academia partnerships, solidifying its leading position in precision oncology.

Gain a Competitive Edge with Our United Kingdom Precision Oncology Market Report 

• The United Kingdom Precision Oncology Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions. 
• This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition. 
• The United Kingdom Precision Oncology Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.

*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.